relmada therapeutics - Search News

Relmada acquires neurosteroid from Asarina

Relmada acquires Tourette’s therapy rights from Asarina

Relmada Therapeutics has acquired complete worldwide ownership rights to Sepranolone from Sweden-based Asarina Pharma. Sepranolone is a neurosteroid being developed as a potential treatment for Tourette's syndrome (TS) and other compulsive disorders.

Business Insider · 4d

Relmada Therapeutics acquires Sepranolone from Asarina Pharma

Relmada Therapeutics (RLMD) announced the acquisition of Sepranolone, a Phase 2b ready neurosteroid, from Asarina Pharma AB, being developed

Investing.com on MSN · 4d

Relmada acquires new Tourette syndrome treatment asset

CORAL GABLES, Fla. - Relmada Therapeutics , Inc. (NASDAQ:RLMD), a clinical-stage biotechnology firm with a market capitalization of $11.5 million, has announced the acquisition of Sepranolone, a Phase 2b ready neurosteroid,

The Pharma Letter · 3d

Relmada in-licenses Tourette syndrome drug from Asarina

US CNS specialist Relmada Therapeutics has announced the acquisition of sepranolone, a Phase IIb ready neurosteroid, from Sweden’s Asarina Pharma, being developed for the potential treatment of Tourette syndrome (TS) and other compulsive disorders.

Business Insider · 4d

Relmada Therapeutics Acquires Potential Therapy for Tourette Syndrome from Asarina Pharma AB

Relmada purchases Sepranolone, a Phase 2b ready asset, for the treatment of Tourette syndrome (TS) and other compulsion-related conditions from

FierceBiotech2d

After phase 3 miss, Relmada picks up midstage Tourette's asset from Swedish biotech

Relmada, which has turned to strategic options after scrapping two phase 3 trials in major depressive disorder (MDD), is ...

Nasdaq4d

Relmada Therapeutics Acquires Sepranolone from Asarina Pharma for Tourette Syndrome Treatment Development

Relmada Therapeutics has announced the acquisition of Sepranolone, a Phase 2b ready neurosteroid developed for treating Tourette syndrome (TS) and related compulsive disorders, from Asarina Pharma ...

Investing2d

Relmada Therapeutics Inc (RLMD)

Revenue for the quarter came in at... Relmada Therapeutics (NASDAQ:RLMD) reported Q4 EPS of ($1.80), $0.03 better than the analyst estimate of ($1.83). For earnings history and earnings-related ...

3don MSN

Mizuho maintains Neutral on Relmada stock, sees deal potential

Mizuho (NYSE:MFG) analysts maintained their Neutral rating on Relmada Therapeutics Inc (NASDAQ:RLMD), with a steady price target of $1.00, following the announcement of a new acquisition. The stock, ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results